Clinical Endoscopy

Review

Sex/gender differences in gastrointestinal endoscopy from the perspective of patients and gastroenterologists: Nayoung Kim; Clin Endosc 2023;56(3):268-282. Published online May 3, 2023; DOI: https://doi.org/10.5946/ce.2022.270

The sex/gender of gastroenterologists impact patients’ satisfaction, compliance, and clinical outcomes. For instance, female gastrointestinal (GI) endoscopist–patient gender concordance improves health-related outcomes. This finding suggests that it is important to increase the number of female GI endoscopists. While the number of women in the field of gastroenterology is increasing in the United States and Korea by over 28.3%, it is not enough to account for the gender preferences of female patients. GI endoscopists are at a high risk of endoscopy-related injuries. However, there is a different distribution of muscle and fat; male endoscopists are more affected in their back, while females are more affected in the upper extremities. Women are more susceptible to endoscopy-related injuries than men. There is a correlation between the number of colonoscopies performed and musculoskeletal pain. Job satisfaction is lower in young female gastroenterologists (30’ and 40’) than in the opposite gender and other ages. Thus, it is important to address these issues in the development of GI endoscopy.

Citations

Citations to this article as recorded by

Protecting Gastroenterologists through Rehabilitation Training: An Overlooked Area of Concern
Sun-Hye Ko, Myong Ki Baeg
Gut and Liver.2023; 17(6): 829. CrossRef

2,693 View
152 Download
1 Web of Science
1 Crossref

Original Articles

Efficacy of Albis for the Prevention of Gastric Mucosal Injury Concomitant with the Use of Low-Dose Aspirin: A Prospective, Randomized, Placebo-Controlled Study: Sang Gyun Kim, Nayoung Kim, Sung Kwan Shin, In Kyung Sung, Su Jin Hong, Hyo-Jin Park; Clin Endosc 2017;50(2):179-184. Published online May 19, 2016; DOI: https://doi.org/10.5946/ce.2016.031

Abstract PDF PubReader ePub

Background
/Aims: Long-term use of aspirin can be a risk factor of peptic ulcer diseases. The aim of this study was to evaluate the efficacy of Albis (Daewoong Pharmaceutical Co., Ltd.) for the prevention of gastric mucosal injury caused by aspirin.
Methods
Aspirin users were enrolled and randomized into the Albis or placebo group. Screening and follow-up endoscopy were performed for modified Lanza scores (MLSs). Primary outcome was measured by the incidence rate of peptic ulcer, and secondary outcomes were measured by the incidence rate of gastritis, improvement in MLS and subjective symptoms.
Results
In total, 81 aspirin users were randomized, 43 in the Albis group and 38 in the placebo group. There was no incidence of peptic ulcer in both groups. The incidence of gastritis was significantly higher in the placebo group (44.4% vs. 10.0%, p=0.003); however, the scores of mucosal edema, hyperemia and hemorrhage were not statistically different between the two groups (p>0.05). The frequency of subjective symptoms were more improved in the Albis group than in the placebo group (p=0.023).
Conclusions
The incidence of gastritis was lower in the group that received low-dose aspirin and Albis. The development of peptic ulcer due to long-term use of aspirin might be prevented with concomitant use of Albis.

Citations

Citations to this article as recorded by

Review on recent advancements in understanding acetylsalicylic acid-induced gastrointestinal injury: mechanisms, medication, and dosage refinement
Jiahui Zhou, Na Li, Xinzhong Li, Jingxue Ye, Min Wang, Guibo Sun
Naunyn-Schmiedeberg's Archives of Pharmacology.2024;[Epub] CrossRef
Xiaojianzhong decoction attenuates gastric mucosal injury by activating the p62/Keap1/Nrf2 signaling pathway to inhibit ferroptosis
Juan Chen, Jiaxiang Zhang, Ting Chen, Shengchuan Bao, Jingtao Li, Hailiang Wei, Xin Hu, Yan Liang, Fanrong Liu, Shuguang Yan
Biomedicine & Pharmacotherapy.2022; 155: 113631. CrossRef
A measure of asymmetry for ordinal square contingency tables with an application to modified LANZA score data
Satoru Shinoda, Kouji Yamamoto, Kouji Tahata, Sadao Tomizawa
Journal of Applied Statistics.2020; 47(7): 1251. CrossRef

8,313 View
173 Download
3 Web of Science
3 Crossref

Correlation of Endoscopic Findings of Gastric Mucosa-Associated Lymphoid Tissue Lymphoma with Recurrence after Complete Remission: Chang Min Lee, Dong Ho Lee, Byung Kyu Ahn, Jae Jin Hwang, Hyuk Yoon, Young Soo Park, Cheol Min Shin, Nayoung Kim; Clin Endosc 2017;50(1):51-57. Published online March 24, 2016; DOI: https://doi.org/10.5946/ce.2016.015

Abstract PDF PubReader ePub

Background
/Aims: In gastric mucosa-associated lymphoid tissue (MALT) lymphoma, the clinical significance of various endoscopic findings has not yet been determined. This study aimed to compare the time to complete remission (CR) and relapse-free survival (RFS) in gastric MALT lymphoma based on endoscopic findings.
Methods
In this single-center retrospective cohort study, the medical records of 122 consecutive adult patients with gastric MALT lymphoma were collected over a period of 12 years. CR was defined by the absence of macroscopic or microscopic features of lymphoma on two subsequent follow-ups. Relapse was clinically defined by a positive endoscopic biopsy after CR.
Results
The median time to CR did not differ significantly between treatment methods. However, it was significantly longer in the group with polypoid endoscopic appearance than in the groups with diffuse infiltration or ulceration (7.83, 3.43, and 3.10 months, respectively; p=0.003). Six patients relapsed after CR. Kaplan-Meier analysis showed that RFS differed significantly between groups based on Ann Arbor staging, treatment methods, and initial endoscopic findings.
Conclusions
In gastric MALT lymphoma, the endoscopically defined polypoid type was characterized by a longer duration to CR, with a higher likelihood of recurrence, compared to the endoscopically defined diffuse infiltration or ulceration types.

Citations

Citations to this article as recorded by

A Case of Gastric Mucosa-Associated Lymphoid Tissue Lymphoma with Special Endoscopic Morphology
Xin Sun, Yanbo Zhen, Pan Pan, Liang Liu
Journal of Digestive Endoscopy.2024;[Epub] CrossRef
Characteristic endoscopic findings of gastrointestinal malignant lymphomas other than mucosa-associated lymphoid tissue lymphoma
T Kanno, T Katano, T Shimura, R Nishigaki, Y Kojima, M Sasaki, Y Okuda, N Sugimura, S Fukusada, Y Mizuno, H Iwasaki, H Nishie, M Tanaka, K Ozeki, E Kubota, S Tanida, H Kataoka
Acta Gastro Enterologica Belgica.2022; 85(3): 477. CrossRef
Diagnosis and Treatment for Gastric Mucosa-Associated Lymphoid Tissue (MALT) Lymphoma
Shotaro Nakamura, Mariko Hojo
Journal of Clinical Medicine.2022; 12(1): 120. CrossRef
Normal gastrointestinal tract inflammatory cells and review of select benign hematolymphoid proliferations
Jennifer Y. Ju, Edward B. Stelow, Elizabeth L. Courville
Seminars in Diagnostic Pathology.2021; 38(4): 6. CrossRef
Optimal Initial Workup in Patients With Superficial Primary Gastric MALT Lymphoma
Hee Kyong Na, Sung Hyun Won, Jeong Hoon Lee, Ga Hee Kim, Kee Wook Jung, Ji Yong Ahn, Do Hoon Kim, Kee Don Choi, Ho June Song, Gin Hyug Lee, Hwoon-Yong Jung
Journal of Clinical Gastroenterology.2021; 55(9): 785. CrossRef
Endoscopic features and clinical outcomes of colorectal mucosa-associated lymphoid tissue lymphoma
Min Kyung Jeon, Hoonsub So, Jooryung Huh, Hee Sang Hwang, Sung Wook Hwang, Sang Hyoung Park, Dong-Hoon Yang, Kee Don Choi, Byong Duk Ye, Seung-Jae Myung, Suk-Kyun Yang, Jeong-Sik Byeon
Gastrointestinal Endoscopy.2018; 87(2): 529. CrossRef
Endoscopic Findings of Gastric Extranodal Marginal Zone B-Cell Mucosa-Associated Lymphoid Tissue Lymphoma
Sang Kil Lee
Clinical Endoscopy.2017; 50(1): 1. CrossRef

9,963 View
226 Download
7 Web of Science
7 Crossref

Low Grade Gastric Mucosa-associated Lymphoid Tissue Lymphoma: Clinicopathological Factors Associated with Helicobacter pylori Eradication and Tumor Regression: Yoon Jin Choi, Dong Ho Lee, Ji Yeon Kim, Ji Eun Kwon, Jae Yeon Kim, Hyun Jin Jo, Cheol Min Shin, Hyun Young Kim, Young Soo Park, Nayoung Kim, Hyun Chae Jung, In Sung Song; Clin Endosc 2011;44(2):101-108. Published online December 31, 2011; DOI: https://doi.org/10.5946/ce.2011.44.2.101

Abstract PDF PubReader ePub

Background/Aims

Eradication of Helicobacter pylori is widely accepted as initial therapy for low-grade gastric mucosa-associated lymphoid tissue (MALT) lymphoma. However, approximately 20% of patients with this disease are not responsive to H. pylori eradication therapy. The aim of this study was to assess remission and relapse rates of low-grade gastric MALT lymphoma after H. pylori eradication and identify the clinical factors that affect remission.

Methods

Thirty-nine patients diagnosed with gastric MALT lymphoma (May 2003 to May 2010) were retrospectively analyzed.

Results

Of the 39 patients, 30 (77%) had a H. pylori infection. There were 35/39 (90%) patients with stage I. Among stage I, 25 patients with the infection underwent eradication therapy and 22/25 (88%) achieved remission. The total regression rate with eradication only in stage I was 24/28 (86%). The median time to remission was 98 days (range, 22 to 397 days). Age, tumor location, invasion depth, H. pylori burden, and severity of mononuclear leukocyte and neutrophil infiltration were not related to remission. However, patients with less neutrophil infiltration were more likely to achieve a successful first H. pylori eradication (p=0.049).

Conclusions

The results show that the rate of low-grade gastric MALT lymphoma regression (86%) with H. pylori eradication alone was higher than that in Western studies (77.8%) and that neutrophil infiltration was inversely related to success of the first H. pylori eradication procedure.

Citations

Citations to this article as recorded by

Effectiveness of Helicobacter pylori eradication in the treatment of early-stage gastric mucosa-associated lymphoid tissue lymphoma: An up-to-date meta-analysis
Fabian Fellipe Bueno Lemos, Caroline Tianeze de Castro, Mariana Santos Calmon, Marcel Silva Luz, Samuel Luca Rocha Pinheiro, Clara Faria Souza Mendes dos Santos, Gabriel Lima Correa Santos, Hanna Santos Marques, Henrique Affonso Delgado, Kádima Nayara Tei
World Journal of Gastroenterology.2023; 29(14): 2202. CrossRef
Efficacy of eradication therapy in Helicobacter pylori‐negative gastric mucosa‐associated lymphoid tissue lymphoma: A meta‐analysis
Kyoungwon Jung, Do Hoon Kim, Hyun Il Seo, Eun Jeong Gong, Chang Seok Bang
Helicobacter.2021;[Epub] CrossRef
Clinical efficacy of the modified Helicobacter pylori eradication therapy for Helicobacter pylori-negative gastric mucosa-associated lymphoid tissue lymphoma: a meta analysis
Ya-Lin Xie, Chun-Yan He, Si-Qi Wei, Wen-Ju Guan, Zheng Jiang
Chinese Medical Journal.2020; 133(11): 1337. CrossRef
Clinical Efficacy of Radiotherapy inHelicobacter pyloriNegative or Unresponsive to Eradication Therapy Primary Gastric Mucosa-Associated Lymphoid Tissue Lymphoma
Byung Sam Park, Si Hyung Lee
The Korean Journal of Gastroenterology.2019; 73(1): 19. CrossRef
Endoscopic features aiding the diagnosis of gastric mucosa-associated lymphoid tissue lymphoma
Byung Sam Park, Si Hyung Lee
Yeungnam University Journal of Medicine.2019; 36(2): 85. CrossRef
Bone marrow involvement is not associated with the clinical outcomes of gastric mucosa-associated lymphoid tissue lymphoma
Eun Jeong Gong, Ji Yong Ahn, Hwoon-Yong Jung, Kyoungwon Jung, Charles J. Cho, Hee Kyong Na, Kee Wook Jung, Do Hoon Kim, Jeong Hoon Lee, Kee Don Choi, Ho June Song, Gin Hyug Lee, Jin-Ho Kim, Dok Hyun Yoon
Scandinavian Journal of Gastroenterology.2016; 51(8): 942. CrossRef
Helicobacter pyloriEradication Therapy Is Effective as the Initial Treatment for Patients withH. pylori-Negative and Disseminated Gastric Mucosa-Associated Lymphoid Tissue Lymphoma
Eun Jeong Gong, Ji Yong Ahn, Hwoon-Yong Jung, Hyungchul Park, Young Bo Ko, Hee Kyong Na, Kee Wook Jung, Do Hoon Kim, Jeong Hoon Lee, Kee Don Choi, Ho June Song, Gin Hyug Lee, Jin-Ho Kim
Gut and Liver.2016; 10(5): 706. CrossRef
Antisecretory medication is associated with decreased Helicobacter pylori detection in gastric marginal zone lymphoma
Kurt B. Schaberg, Mark F. Evans, Rebecca Wilcox, Michael R. Lewis
Annals of Diagnostic Pathology.2015; 19(6): 397. CrossRef
A Polypoid Mucosa-Associated Lymphoid Tissue Lymphoma of the Stomach Treated with Endoscopic Polypectomy
Shin Young Min, Jun Haeng Lee, Poong-Lyul Rhee
Clinical Endoscopy.2013; 46(6): 647. CrossRef

8,338 View
53 Download
9 Crossref

Dual Therapy Trial Using Esomeprazole and Amoxicillin as Third-line Rescue Therapy for Helicobacter pylori Infection: Hyun Kyung Park, Dong Ho Lee, Seungchul Suh, Pyoung Ju Seo, Nayoung Kim, Sook-Hyang Jeong, Jin-Wook Kim, Jin-Hyeok Hwang, Young Soo Park, Sang Hyub Lee, Cheol Min Shin; Clin Endosc 2011;44(1):33-37. Published online September 30, 2011; DOI: https://doi.org/10.5946/ce.2011.44.1.33

Abstract PDF PubReader ePub

Background/Aims

The purpose of this study was to evaluate the efficacy and tolerability of dual therapy consisting of esomeprazole and amoxicillin as a rescue therapy for Helicobacter pylori infection.

Methods

From December 2009 to August 2010, 21 patients who experienced two consecutive eradication failures were included. They received esomeprazole (40 mg, b.i.d.) and amoxicillin (1,000 mg, b.i.d.) for 14 days as a third eradication regimen. Compliance and side effects were determined from an interview. H. pylori status was evaluated using the ¹³C urea breath test at least 6 weeks after treatment.

Results

The mean age of the patients was 59 years and included 52% males. Indications for treatment were functional dyspepsia (61.9%), peptic ulcer disease (28.6%), and gastric adenoma (9.5%). H. pylori was eradicated in 14 of 21 (66.7%) patients. Minor side effects were reported in three of the 21 patients (14.3%). These side effects consisted mainly of nausea and epigastric discomfort.

Conclusions

A 2-week course of dual therapy failed to show satisfactory results in third-line H. pylori eradication, but it was very safe and tolerable. Therefore, dual therapy constitutes an encouraging empirical strategy for the elderly and infirm patients with multiple previous eradication failures.

Citations

Citations to this article as recorded by

Dual therapy for Helicobacter pylori infection
Miao Duan, Jing Liu, Xiuli Zuo
Chinese Medical Journal.2023;[Epub] CrossRef
Helicobacter pylori Antimicrobial Susceptibility Testing-Guided Salvage Therapy in the USA: A Real Life Experience
Bei Tan, Jyh-Chin Yang, Carol L. Young, Shrinivas Bishu, Stephanie Y. Owyang, Mohamad El-Zaatari, Min Zhang, Helmut Grasberger, Jia-ming Qian, John Y. Kao
Digestive Diseases and Sciences.2018; 63(2): 437. CrossRef
Treatment of Helicobacter pylori Infection in Korea: A Systematic Review and Meta-analysis
Sang Wook Lee, Hyun Jung Kim, Jae Gyu Kim
Journal of Korean Medical Science.2015; 30(8): 1001. CrossRef

6,840 View
48 Download
3 Crossref

First
Prev
Page of 1
Next
Last

Search